184 related articles for article (PubMed ID: 29088253)
1. A composite docking approach for the identification and characterization of ectosteric inhibitors of cathepsin K.
Law S; Panwar P; Li J; Aguda AH; Jamroz A; Guido RVC; Brömme D
PLoS One; 2017; 12(10):e0186869. PubMed ID: 29088253
[TBL] [Abstract][Full Text] [Related]
2. Tanshinones that selectively block the collagenase activity of cathepsin K provide a novel class of ectosteric antiresorptive agents for bone.
Panwar P; Law S; Jamroz A; Azizi P; Zhang D; Ciufolini M; Brömme D
Br J Pharmacol; 2018 Mar; 175(6):902-923. PubMed ID: 29278432
[TBL] [Abstract][Full Text] [Related]
3. Identification of substrate-specific inhibitors of cathepsin K through high-throughput screening.
Law S; Du X; Panwar P; Honson NS; Pfeifer T; Roberge M; Brömme D
Biochem J; 2019 Feb; 476(3):499-512. PubMed ID: 30622151
[TBL] [Abstract][Full Text] [Related]
4. An Ectosteric Inhibitor of Cathepsin K Inhibits Bone Resorption in Ovariectomized Mice.
Panwar P; Xue L; Søe K; Srivastava K; Law S; Delaisse JM; Brömme D
J Bone Miner Res; 2017 Dec; 32(12):2415-2430. PubMed ID: 28745432
[TBL] [Abstract][Full Text] [Related]
5. Green asymmetric synthesis of epoxypeptidomimetics and evaluation as human cathepsin K inhibitors.
Silva TL; Dos Santos DA; de Jesus HCR; Brömme D; Fernandes JB; Paixão MW; Corrêa AG; Vieira PC
Bioorg Med Chem; 2020 Aug; 28(15):115597. PubMed ID: 32631567
[TBL] [Abstract][Full Text] [Related]
6. Pharmacological inhibition of cathepsin K: A promising novel approach for postmenopausal osteoporosis therapy.
Mukherjee K; Chattopadhyay N
Biochem Pharmacol; 2016 Oct; 117():10-9. PubMed ID: 27106079
[TBL] [Abstract][Full Text] [Related]
7. Heparan sulfate selectively inhibits the collagenase activity of cathepsin K.
Zhang X; Luo Y; Hao H; Krahn JM; Su G; Dutcher R; Xu Y; Liu J; Pedersen LC; Xu D
Matrix Biol; 2024 May; 129():15-28. PubMed ID: 38548090
[TBL] [Abstract][Full Text] [Related]
8. A novel approach to inhibit bone resorption: exosite inhibitors against cathepsin K.
Panwar P; Søe K; Guido RV; Bueno RV; Delaisse JM; Brömme D
Br J Pharmacol; 2016 Jan; 173(2):396-410. PubMed ID: 26562357
[TBL] [Abstract][Full Text] [Related]
9. A Mild Inhibition of Cathepsin K Paradoxically Stimulates the Resorptive Activity of Osteoclasts in Culture.
Pirapaharan DC; Søe K; Panwar P; Madsen JS; Bergmann ML; Overgaard M; Brömme D; Delaisse JM
Calcif Tissue Int; 2019 Jan; 104(1):92-101. PubMed ID: 30194476
[TBL] [Abstract][Full Text] [Related]
10. Structural requirements for the collagenase and elastase activity of cathepsin K and its selective inhibition by an exosite inhibitor.
Sharma V; Panwar P; O'Donoghue AJ; Cui H; Guido RV; Craik CS; Brömme D
Biochem J; 2015 Jan; 465(1):163-73. PubMed ID: 25279554
[TBL] [Abstract][Full Text] [Related]
11. Advances in the discovery of cathepsin K inhibitors on bone resorption.
Lu J; Wang M; Wang Z; Fu Z; Lu A; Zhang G
J Enzyme Inhib Med Chem; 2018 Dec; 33(1):890-904. PubMed ID: 29723068
[TBL] [Abstract][Full Text] [Related]
12. Dioxo-triazines as a novel series of cathepsin K inhibitors.
Rankovic Z; Cai J; Fradera X; Dempster M; Mistry A; Mitchell A; Long C; Hamilton E; King A; Boucharens S; Jamieson C; Gillespie J; Cumming I; Uitdehaag J; van Zeeland M
Bioorg Med Chem Lett; 2010 Mar; 20(5):1488-90. PubMed ID: 20153187
[TBL] [Abstract][Full Text] [Related]
13. Clinical and translational pharmacology of the cathepsin K inhibitor odanacatib studied for osteoporosis.
Stone JA; McCrea JB; Witter R; Zajic S; Stoch SA
Br J Clin Pharmacol; 2019 Jun; 85(6):1072-1083. PubMed ID: 30663085
[TBL] [Abstract][Full Text] [Related]
14. Cathepsin K inhibitors for osteoporosis and potential off-target effects.
Brömme D; Lecaille F
Expert Opin Investig Drugs; 2009 May; 18(5):585-600. PubMed ID: 19388876
[TBL] [Abstract][Full Text] [Related]
15. The role of basic amino acid surface clusters on the collagenase activity of cathepsin K.
Nallaseth FS; Lecaille F; Li Z; Brömme D
Biochemistry; 2013 Nov; 52(44):7742-52. PubMed ID: 24088021
[TBL] [Abstract][Full Text] [Related]
16. Nonclinical and clinical pharmacological characterization of the potent and selective cathepsin K inhibitor MIV-711.
Lindström E; Rizoska B; Henderson I; Terelius Y; Jerling M; Edenius C; Grabowska U
J Transl Med; 2018 May; 16(1):125. PubMed ID: 29743078
[TBL] [Abstract][Full Text] [Related]
17. An Activity-Based Probe for Cathepsin K Imaging with Excellent Potency and Selectivity.
Lemke C; Benýšek J; Brajtenbach D; Breuer C; Jílková A; Horn M; Buša M; Ulrychová L; Illies A; Kubatzky KF; Bartz U; Mareš M; Gütschow M
J Med Chem; 2021 Sep; 64(18):13793-13806. PubMed ID: 34473502
[TBL] [Abstract][Full Text] [Related]
18. A potent small molecule, nonpeptide inhibitor of cathepsin K (SB 331750) prevents bone matrix resorption in the ovariectomized rat.
Lark MW; Stroup GB; James IE; Dodds RA; Hwang SM; Blake SM; Lechowska BA; Hoffman SJ; Smith BR; Kapadia R; Liang X; Erhard K; Ru Y; Dong X; Marquis RW; Veber D; Gowen M
Bone; 2002 May; 30(5):746-53. PubMed ID: 11996914
[TBL] [Abstract][Full Text] [Related]
19. The Alkyne Moiety as a Latent Electrophile in Irreversible Covalent Small Molecule Inhibitors of Cathepsin K.
Mons E; Jansen IDC; Loboda J; van Doodewaerd BR; Hermans J; Verdoes M; van Boeckel CAA; van Veelen PA; Turk B; Turk D; Ovaa H
J Am Chem Soc; 2019 Feb; 141(8):3507-3514. PubMed ID: 30689386
[TBL] [Abstract][Full Text] [Related]
20. Potent and selective inhibition of human cathepsin K leads to inhibition of bone resorption in vivo in a nonhuman primate.
Stroup GB; Lark MW; Veber DF; Bhattacharyya A; Blake S; Dare LC; Erhard KF; Hoffman SJ; James IE; Marquis RW; Ru Y; Vasko-Moser JA; Smith BR; Tomaszek T; Gowen M
J Bone Miner Res; 2001 Oct; 16(10):1739-46. PubMed ID: 11585335
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
